Dillman R O
Hoag Cancer Center, Newport Beach, CA 92663.
J Clin Oncol. 1994 Jul;12(7):1497-515. doi: 10.1200/JCO.1994.12.7.1497.
This review was conducted to characterize the results of trials of unconjugated monoclonal antibodies in the treatment of cancer. This survey does not cover antibodies conjugated to drugs, isotopes, or toxins.
An English-language literature search was used to identify reports of trials of unconjugated monoclonal antibodies in patients with cancer.
Most trials have been pilot or phase I to II in nature. The most encouraging results have been described for various antibodies directed against lymphoma, and for certain monoclonal antibodies that bind to glycolipid antigens on melanoma, sarcoma, and neuroblastoma. Toxicity has not been a major problem with these reagents, but human antimouse antibodies have limited the potential application of murine reagents.
At present, there are no unconjugated monoclonal antibodies that have proven therapeutic benefit in hematologic malignancies or solid tumors. The most active areas of current interest relate to antibodies to various growth factor receptors and the testing of humanized antibodies.
本综述旨在描述未偶联单克隆抗体治疗癌症的试验结果。本调查不涵盖与药物、同位素或毒素偶联的抗体。
通过英文文献检索，确定未偶联单克隆抗体治疗癌症患者的试验报告。
大多数试验本质上是试点试验或I至II期试验。针对淋巴瘤的各种抗体以及某些与黑色素瘤、肉瘤和神经母细胞瘤上的糖脂抗原结合的单克隆抗体已取得最令人鼓舞的结果。这些试剂的毒性并非主要问题，但人抗鼠抗体限制了鼠源试剂的潜在应用。
目前，尚无已证明对血液系统恶性肿瘤或实体瘤有治疗益处的未偶联单克隆抗体。当前最受关注的活跃领域涉及针对各种生长因子受体的抗体以及人源化抗体的测试。
